

## CHOICE OF PATIENTS WHOM OMALIZUMAB THERAPY IS INDICATED FOR

*L.I. Romaniuk*

**Resume.** *According to GINA-2009 omalizumab (Xolair) is used for treatment of moderate to severe IgE-mediated BA on stage 5 of therapy. In the latest recommendations the high doses of omalizumab are approved in patients with allergic BA and correlation of the IgE/body mass outside the initially accepted dosing tables. Omalizumab has a good safety profile in children of 6-12 years. There is experience of omalizumab therapy of AR and AD in patients with high levels of IgE.*

**Key words:** *severe asthma, atopic asthma, omalizumab (Xolair), level of serum IgE, safety profile.*